1. Home
  2. XYLO vs RNAZ Comparison

XYLO vs RNAZ Comparison

Compare XYLO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XYLO
  • RNAZ
  • Stock Information
  • Founded
  • XYLO 1999
  • RNAZ 2016
  • Country
  • XYLO Israel
  • RNAZ United States
  • Employees
  • XYLO N/A
  • RNAZ N/A
  • Industry
  • XYLO
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • XYLO
  • RNAZ Health Care
  • Exchange
  • XYLO NYSE
  • RNAZ Nasdaq
  • Market Cap
  • XYLO 6.5M
  • RNAZ 6.1M
  • IPO Year
  • XYLO N/A
  • RNAZ 2021
  • Fundamental
  • Price
  • XYLO $5.13
  • RNAZ $9.16
  • Analyst Decision
  • XYLO
  • RNAZ Strong Buy
  • Analyst Count
  • XYLO 0
  • RNAZ 1
  • Target Price
  • XYLO N/A
  • RNAZ $280.00
  • AVG Volume (30 Days)
  • XYLO 2.8K
  • RNAZ 26.4K
  • Earning Date
  • XYLO 07-15-2025
  • RNAZ 08-13-2025
  • Dividend Yield
  • XYLO N/A
  • RNAZ N/A
  • EPS Growth
  • XYLO N/A
  • RNAZ N/A
  • EPS
  • XYLO N/A
  • RNAZ N/A
  • Revenue
  • XYLO $29,858,000.00
  • RNAZ N/A
  • Revenue This Year
  • XYLO $279.19
  • RNAZ N/A
  • Revenue Next Year
  • XYLO N/A
  • RNAZ N/A
  • P/E Ratio
  • XYLO N/A
  • RNAZ N/A
  • Revenue Growth
  • XYLO N/A
  • RNAZ N/A
  • 52 Week Low
  • XYLO $2.70
  • RNAZ $6.15
  • 52 Week High
  • XYLO $6.67
  • RNAZ $905.52
  • Technical
  • Relative Strength Index (RSI)
  • XYLO 49.39
  • RNAZ 59.41
  • Support Level
  • XYLO $4.98
  • RNAZ $8.04
  • Resistance Level
  • XYLO $5.11
  • RNAZ $9.70
  • Average True Range (ATR)
  • XYLO 0.13
  • RNAZ 0.65
  • MACD
  • XYLO 0.00
  • RNAZ 0.38
  • Stochastic Oscillator
  • XYLO 63.16
  • RNAZ 93.67

About XYLO XYLO TECHNOLOGIES LTD

Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: